| 货号 | 名称 | | 克隆 | 反应性 | 抗原 | 宿主 | 同型 | 免疫原 |
| BE0300-100MG | InVivoMAb anti-mouse CD45.2 | | 104.2 | mouse | CD45.2 | mouse | IgG2a, κ | B10.S mouse thymocytes ａnd splenocytes |
| BE0300-1MG | InVivoMAb anti-mouse CD45.2 | | 104.2 | mouse | CD45.2 | mouse | IgG2a, κ | B10.S mouse thymocytes ａnd splenocytes |
| BE0300-5MG | InVivoMAb anti-mouse CD45.2 | | 104.2 | mouse | CD45.2 | mouse | IgG2a, κ | B10.S mouse thymocytes ａnd splenocytes |
| BE0300-25MG | InVivoMAb anti-mouse CD45.2 | | 104.2 | mouse | CD45.2 | mouse | IgG2a, κ | B10.S mouse thymocytes ａnd splenocytes |
| BE0300-50MG | InVivoMAb anti-mouse CD45.2 | | 104.2 | mouse | CD45.2 | mouse | IgG2a, κ | B10.S mouse thymocytes ａnd splenocytes |
| BE0301-100MG | InVivoMAb human IgG2 isotype control | | n/a | n/a | Unknown Specificify | human | IgG2 | |
| BE0301-1MG | InVivoMAb human IgG2 isotype control | | n/a | n/a | Unknown Specificify | human | IgG2 | |
| BE0301-5MG | InVivoMAb human IgG2 isotype control | | n/a | n/a | Unknown Specificify | human | IgG2 | |
| BE0301-25MG | InVivoMAb human IgG2 isotype control | | n/a | n/a | Unknown Specificify | human | IgG2 | |
| BE0301-50MG | InVivoMAb human IgG2 isotype control | | n/a | n/a | Unknown Specificify | human | IgG2 | |
| BE0302-100MG | InVivoMAb anti-mouse CD20 | | AISB12 | mouse | CD20 | rat | IgG2a, κ | Full length mouse CD20 protein |
| BE0302-25MG | InVivoMAb anti-mouse CD20 | | AISB12 | mouse | CD20 | rat | IgG2a, κ | Full length mouse CD20 protein |
| BE0302-50MG | InVivoMAb anti-mouse CD20 | | AISB12 | mouse | CD20 | rat | IgG2a, κ | Full length mouse CD20 protein |
| BE0303-100MG | InVivoMAb anti-mouse IL-17F | | MM17F8F5.1A9 | mouse | IL-17F | mouse | IgG1, κ | Mouse IL-17F |
| BE0303-1MG | InVivoMAb anti-mouse IL-17F | | MM17F8F5.1A9 | mouse | IL-17F | mouse | IgG1, κ | Mouse IL-17F |
| BE0303-5MG | InVivoMAb anti-mouse IL-17F | | MM17F8F5.1A9 | mouse | IL-17F | mouse | IgG1, κ | Mouse IL-17F |
| BE0303-25MG | InVivoMAb anti-mouse IL-17F | | MM17F8F5.1A9 | mouse | IL-17F | mouse | IgG1, κ | Mouse IL-17F |
| BE0303-50MG | InVivoMAb anti-mouse IL-17F | | MM17F8F5.1A9 | mouse | IL-17F | mouse | IgG1, κ | Mouse IL-17F |
| BE0304-100MG | InVivoMAb anti-mouse BTLA (CD272) | | 6F7 | mouse | BTLA (CD272) | mouse | IgG1, κ | Ig domain of C57BL/6 mouse BTLA |
| BE0304-1MG | InVivoMAb anti-mouse BTLA (CD272) | | 6F7 | mouse | BTLA (CD272) | mouse | IgG1, κ | Ig domain of C57BL/6 mouse BTLA |
| BE0304-5MG | InVivoMAb anti-mouse BTLA (CD272) | | 6F7 | mouse | BTLA (CD272) | mouse | IgG1, κ | Ig domain of C57BL/6 mouse BTLA |
| BE0304-25MG | InVivoMAb anti-mouse BTLA (CD272) | | 6F7 | mouse | BTLA (CD272) | mouse | IgG1, κ | Ig domain of C57BL/6 mouse BTLA |
| BE0304-50MG | InVivoMAb anti-mouse BTLA (CD272) | | 6F7 | mouse | BTLA (CD272) | mouse | IgG1, κ | Ig domain of C57BL/6 mouse BTLA |
| BE0305-100MG | InVivoMAb anti-mouse CLEC9A (CD370) | | 7H11 | mouse | CLEC9A (CD370) | Rat | IgG1, κ | RBL-2H3 cells expressing mouse CLEC9A fused to an HA epie |
| BE0305-1MG | InVivoMAb anti-mouse CLEC9A (CD370) | | 7H11 | mouse | CLEC9A (CD370) | Rat | IgG1, κ | RBL-2H3 cells expressing mouse CLEC9A fused to an HA epie |
| BE0305-5MG | InVivoMAb anti-mouse CLEC9A (CD370) | | 7H11 | mouse | CLEC9A (CD370) | Rat | IgG1, κ | RBL-2H3 cells expressing mouse CLEC9A fused to an HA epie |
| BE0305-25MG | InVivoMAb anti-mouse CLEC9A (CD370) | | 7H11 | mouse | CLEC9A (CD370) | Rat | IgG1, κ | RBL-2H3 cells expressing mouse CLEC9A fused to an HA epie |
| BE0305-50MG | InVivoMAb anti-mouse CLEC9A (CD370) | | 7H11 | mouse | CLEC9A (CD370) | Rat | IgG1, κ | RBL-2H3 cells expressing mouse CLEC9A fused to an HA epie |
| BE0306-100MG | InVivoMAb anti-human/monkey MHC class II (HLA-DR) | | L243 | human/monkey | MHC class II (HLA-DR) | Mouse | IgG2a, κ | Human lymphoblastoid B cell line RPMI 8866.9 |
| BE0306-1MG | InVivoMAb anti-human/monkey MHC class II (HLA-DR) | | L243 | human/monkey | MHC class II (HLA-DR) | Mouse | IgG2a, κ | Human lymphoblastoid B cell line RPMI 8866.9 |
| BE0306-5MG | InVivoMAb anti-human/monkey MHC class II (HLA-DR) | | L243 | human/monkey | MHC class II (HLA-DR) | Mouse | IgG2a, κ | Human lymphoblastoid B cell line RPMI 8866.9 |
| BE0306-25MG | InVivoMAb anti-human/monkey MHC class II (HLA-DR) | | L243 | human/monkey | MHC class II (HLA-DR) | Mouse | IgG2a, κ | Human lymphoblastoid B cell line RPMI 8866.9 |
| BE0306-50MG | InVivoMAb anti-human/monkey MHC class II (HLA-DR) | | L243 | human/monkey | MHC class II (HLA-DR) | Mouse | IgG2a, κ | Human lymphoblastoid B cell line RPMI 8866.9 |
| BE0307-100MG | InVivoMAb anti-mouse CD16/CD32 | | 2.4G2 | mouse | CD16/CD32 | Rat | IgG2b, κ | BALB/c mouse macrophage cell line J774 |
| BE0307-5MG | InVivoMAb anti-mouse CD16/CD32 | | 2.4G2 | mouse | CD16/CD32 | Rat | IgG2b, κ | BALB/c mouse macrophage cell line J774 |
| BE0307-25MG | InVivoMAb anti-mouse CD16/CD32 | | 2.4G2 | mouse | CD16/CD32 | Rat | IgG2b, κ | BALB/c mouse macrophage cell line J774 |
| BE0307-50MG | InVivoMAb anti-mouse CD16/CD32 | | 2.4G2 | mouse | CD16/CD32 | Rat | IgG2b, κ | BALB/c mouse macrophage cell line J774 |
| BE0308-100MG | InVivoMAb anti-rat CD4 | | OX-38 | rat | CD4 | Mouse | IgG2a, κ | Rat thymocyte glycoproteins |
| BE0308-1MG | InVivoMAb anti-rat CD4 | | OX-38 | rat | CD4 | Mouse | IgG2a, κ | Rat thymocyte glycoproteins |
| BE0308-5MG | InVivoMAb anti-rat CD4 | | OX-38 | rat | CD4 | Mouse | IgG2a, κ | Rat thymocyte glycoproteins |
| BE0308-25MG | InVivoMAb anti-rat CD4 | | OX-38 | rat | CD4 | Mouse | IgG2a, κ | Rat thymocyte glycoproteins |
| BE0308-50MG | InVivoMAb anti-rat CD4 | | OX-38 | rat | CD4 | Mouse | IgG2a, κ | Rat thymocyte glycoproteins |
| BE0309-100MG | InVivoMAb anti-mouse CXCL9 (MIG) | | MIG-2F5.5 | mouse | CXCL9 (MIG) | Armenian hamster | IgG, κ | |
| BE0309-1MG | InVivoMAb anti-mouse CXCL9 (MIG) | | MIG-2F5.5 | mouse | CXCL9 (MIG) | Armenian hamster | IgG, κ | |
| BE0309-5MG | InVivoMAb anti-mouse CXCL9 (MIG) | | MIG-2F5.5 | mouse | CXCL9 (MIG) | Armenian hamster | IgG, κ | |
| BE0309-25MG | InVivoMAb anti-mouse CXCL9 (MIG) | | MIG-2F5.5 | mouse | CXCL9 (MIG) | Armenian hamster | IgG, κ | |
| BE0309-50MG | InVivoMAb anti-mouse CXCL9 (MIG) | | MIG-2F5.5 | mouse | CXCL9 (MIG) | Armenian hamster | IgG, κ | |
| BE0310-100MG | InVivoMAb anti-mouse VISTA | | 13F3 | mouse | VISTA | Armenian hamster | IgG | EL4 cells overexpressing mouse VISTA-RFP ａnd then boosted with VISTA-Ig fusion protein |
| BE0310-1MG | InVivoMAb anti-mouse VISTA | | 13F3 | mouse | VISTA | Armenian hamster | IgG | EL4 cells overexpressing mouse VISTA-RFP ａnd then boosted with VISTA-Ig fusion protein |
| BE0310-5MG | InVivoMAb anti-mouse VISTA | | 13F3 | mouse | VISTA | Armenian hamster | IgG | EL4 cells overexpressing mouse VISTA-RFP ａnd then boosted with VISTA-Ig fusion protein |
| BE0310-25MG | InVivoMAb anti-mouse VISTA | | 13F3 | mouse | VISTA | Armenian hamster | IgG | EL4 cells overexpressing mouse VISTA-RFP ａnd then boosted with VISTA-Ig fusion protein |
| BE0310-50MG | InVivoMAb anti-mouse VISTA | | 13F3 | mouse | VISTA | Armenian hamster | IgG | EL4 cells overexpressing mouse VISTA-RFP ａnd then boosted with VISTA-Ig fusion protein |
| BE0311-100MG | InVivoMAb anti-mouse CD317 (BST2, PDCA-1) | | 927 | mouse | CD317 (BST2, PDCA-1) | Rat | IgG2b, κ | Mouse type I IFN-producing cells |
| BE0311-1MG | InVivoMAb anti-mouse CD317 (BST2, PDCA-1) | | 927 | mouse | CD317 (BST2, PDCA-1) | Rat | IgG2b, κ | Mouse type I IFN-producing cells |
| BE0311-5MG | InVivoMAb anti-mouse CD317 (BST2, PDCA-1) | | 927 | mouse | CD317 (BST2, PDCA-1) | Rat | IgG2b, κ | Mouse type I IFN-producing cells |
| BE0311-25MG | InVivoMAb anti-mouse CD317 (BST2, PDCA-1) | | 927 | mouse | CD317 (BST2, PDCA-1) | Rat | IgG2b, κ | Mouse type I IFN-producing cells |
| BE0311-50MG | InVivoMAb anti-mouse CD317 (BST2, PDCA-1) | | 927 | mouse | CD317 (BST2, PDCA-1) | Rat | IgG2b, κ | Mouse type I IFN-producing cells |
| BE0312-100MG | InVivoMAb anti-mouse IFNγ | | H22 | mouse | IFNγ | Armenian hamster | IgG | Recombinant full-length murine IFNγ |
| BE0312-1MG | InVivoMAb anti-mouse IFNγ | | H22 | mouse | IFNγ | Armenian hamster | IgG | Recombinant full-length murine IFNγ |
| BE0312-5MG | InVivoMAb anti-mouse IFNγ | | H22 | mouse | IFNγ | Armenian hamster | IgG | Recombinant full-length murine IFNγ |
| BE0312-25MG | InVivoMAb anti-mouse IFNγ | | H22 | mouse | IFNγ | Armenian hamster | IgG | Recombinant full-length murine IFNγ |
| BE0312-50MG | InVivoMAb anti-mouse IFNγ | | H22 | mouse | IFNγ | Armenian hamster | IgG | Recombinant full-length murine IFNγ |
| BE0313-100MG | InVivoMAb anti-mouse IL-23 (p19) | | G23-8 | mouse | IL-23 (p19) | Rat | IgG1, κ | Insect cell-expressed, recombinant mouse IL-23 heterodimer |
| BE0313-25MG | InVivoMAb anti-mouse IL-23 (p19) | | G23-8 | mouse | IL-23 (p19) | Rat | IgG1, κ | Insect cell-expressed, recombinant mouse IL-23 heterodimer |
| BE0313-50MG | InVivoMAb anti-mouse IL-23 (p19) | | G23-8 | mouse | IL-23 (p19) | Rat | IgG1, κ | Insect cell-expressed, recombinant mouse IL-23 heterodimer |
| BE0314-100MG | InVivoMAb anti-mouse TIM-1 (CD365) | | 3D10 | mouse | TIM-1 (CD365) | Rat | IgG1, κ | Mouse TIM-1 (signal ａnd IgV domains)/mouse IgG2a Fc fusion protein |
| BE0314-1MG | InVivoMAb anti-mouse TIM-1 (CD365) | | 3D10 | mouse | TIM-1 (CD365) | Rat | IgG1, κ | Mouse TIM-1 (signal ａnd IgV domains)/mouse IgG2a Fc fusion protein |
| BE0314-5MG | InVivoMAb anti-mouse TIM-1 (CD365) | | 3D10 | mouse | TIM-1 (CD365) | Rat | IgG1, κ | Mouse TIM-1 (signal ａnd IgV domains)/mouse IgG2a Fc fusion protein |
| BE0314-25MG | InVivoMAb anti-mouse TIM-1 (CD365) | | 3D10 | mouse | TIM-1 (CD365) | Rat | IgG1, κ | Mouse TIM-1 (signal ａnd IgV domains)/mouse IgG2a Fc fusion protein |
| BE0314-50MG | InVivoMAb anti-mouse TIM-1 (CD365) | | 3D10 | mouse | TIM-1 (CD365) | Rat | IgG1, κ | Mouse TIM-1 (signal ａnd IgV domains)/mouse IgG2a Fc fusion protein |
| BE0315-100MG | InVivoMAb anti-mouse IL-15 | | AIO.3 | mouse | IL-15 | Rat | IgG2a, κ | Recombinant mouse IL-15 |
| BE0315-25MG | InVivoMAb anti-mouse IL-15 | | AIO.3 | mouse | IL-15 | Rat | IgG2a, κ | Recombinant mouse IL-15 |
| BE0315-50MG | InVivoMAb anti-mouse IL-15 | | AIO.3 | mouse | IL-15 | Rat | IgG2a, κ | Recombinant mouse IL-15 |
| BE0316-100MG | InVivoMAb anti-mouse CCR3 (CD193) | | 6S2-19-4 | mouse | CCR3 (CD193) | Rat | IgG2b, λ | Y3 cells expressing full length mouse CCR3 |
| BE0316-1MG | InVivoMAb anti-mouse CCR3 (CD193) | | 6S2-19-4 | mouse | CCR3 (CD193) | Rat | IgG2b, λ | Y3 cells expressing full length mouse CCR3 |
| BE0316-5MG | InVivoMAb anti-mouse CCR3 (CD193) | | 6S2-19-4 | mouse | CCR3 (CD193) | Rat | IgG2b, λ | Y3 cells expressing full length mouse CCR3 |
| BE0316-25MG | InVivoMAb anti-mouse CCR3 (CD193) | | 6S2-19-4 | mouse | CCR3 (CD193) | Rat | IgG2b, λ | Y3 cells expressing full length mouse CCR3 |
| BE0316-50MG | InVivoMAb anti-mouse CCR3 (CD193) | | 6S2-19-4 | mouse | CCR3 (CD193) | Rat | IgG2b, λ | Y3 cells expressing full length mouse CCR3 |
| BE0317-100MG | InVivoMAb anti-mouse CD38 | | NIMR5 | mouse | CD38 | Rat | IgG2a, κ | BCL1 plasma membrane glycoproteins |
| BE0317-1MG | InVivoMAb anti-mouse CD38 | | NIMR5 | mouse | CD38 | Rat | IgG2a, κ | BCL1 plasma membrane glycoproteins |
| BE0317-5MG | InVivoMAb anti-mouse CD38 | | NIMR5 | mouse | CD38 | Rat | IgG2a, κ | BCL1 plasma membrane glycoproteins |
| BE0317-25MG | InVivoMAb anti-mouse CD38 | | NIMR5 | mouse | CD38 | Rat | IgG2a, κ | BCL1 plasma membrane glycoproteins |
| BE0317-50MG | InVivoMAb anti-mouse CD38 | | NIMR5 | mouse | CD38 | Rat | IgG2a, κ | BCL1 plasma membrane glycoproteins |
| BE0318-100MG | InVivoMAb anti-human Ganglioside GD2 | | 14G2a | human | Ganglioside GD2 | Mouse | IgG2a, κ | Neuroblastoma cell line LAN-1 |
| BE0318-1MG | InVivoMAb anti-human Ganglioside GD2 | | 14G2a | human | Ganglioside GD2 | Mouse | IgG2a, κ | Neuroblastoma cell line LAN-1 |
| BE0318-5MG | InVivoMAb anti-human Ganglioside GD2 | | 14G2a | human | Ganglioside GD2 | Mouse | IgG2a, κ | Neuroblastoma cell line LAN-1 |
| BE0318-25MG | InVivoMAb anti-human Ganglioside GD2 | | 14G2a | human | Ganglioside GD2 | Mouse | IgG2a, κ | Neuroblastoma cell line LAN-1 |
| BE0318-50MG | InVivoMAb anti-human Ganglioside GD2 | | 14G2a | human | Ganglioside GD2 | Mouse | IgG2a, κ | Neuroblastoma cell line LAN-1 |
在线咨询
